-
公开(公告)号:US20240360077A1
公开(公告)日:2024-10-31
申请号:US18537093
申请日:2023-12-12
申请人: Aeromics, Inc.
发明人: Marc F. Pelletier , George William Farr , Paul Robert McGuirk , Christopher H. Hall , Walter F. Boron
IPC分类号: C07C235/64 , A61K31/167 , A61K31/24 , A61K31/5375 , A61K31/661 , A61K31/6615 , C07D295/185 , C07F9/12
CPC分类号: C07C235/64 , A61K31/167 , A61K31/24 , A61K31/5375 , A61K31/661 , A61K31/6615 , C07D295/185 , C07F9/12
摘要: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases ofwater imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and/or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and/or tissue hydration, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.
-
公开(公告)号:US12121524B2
公开(公告)日:2024-10-22
申请号:US16962441
申请日:2019-01-16
IPC分类号: A61K31/5377 , A61K9/00 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5375 , A61K31/7088 , A61K38/46 , A61P43/00 , C07D413/12 , C12N9/22 , C12N15/11
CPC分类号: A61K31/5377 , A61K9/0019 , A61K9/0053 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5375 , A61K31/7088 , A61K38/465 , A61P43/00 , C07D413/12 , C12N9/22 , C12N15/11 , C12N2310/20 , C12N2320/31 , C12N2320/32 , C12N2320/35 , C12N2800/80
摘要: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions, or disorders.
-
公开(公告)号:US12121523B2
公开(公告)日:2024-10-22
申请号:US17896774
申请日:2022-08-26
IPC分类号: A61K31/5375 , A61K31/00
CPC分类号: A61K31/5375 , A61K31/00
摘要: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
-
公开(公告)号:US20240308954A1
公开(公告)日:2024-09-19
申请号:US18549986
申请日:2022-03-11
申请人: BIOMEDCODE HELLAS SA
发明人: George Kollias , Niki Karagianni , Maria C. Denis , Alexios N. Matralis , Dimitra Papadopoulou , Eleni Karkoulia
IPC分类号: C07C237/44 , A61K31/166 , A61K31/353 , A61K31/44 , A61K31/4418 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P29/00 , C07C231/02 , C07D211/38 , C07D213/40 , C07D213/82 , C07D241/44 , C07D295/135 , C07D311/58 , C07D471/04
CPC分类号: C07C237/44 , A61K31/166 , A61K31/353 , A61K31/44 , A61K31/4418 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61P29/00 , C07C231/02 , C07D211/38 , C07D213/40 , C07D213/82 , C07D241/44 , C07D295/135 , C07D311/58 , C07D471/04 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18
摘要: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate, or isomer thereof. Pharmaceutical compositions comprising the compounds of formula (I) as well as their use in therapy, particularly in the treatment of inflammatory conditions. Advantageously, the compounds show a broad and robust anti-inflammatory effect, and are therapeutically safe.
-
公开(公告)号:US20240254075A1
公开(公告)日:2024-08-01
申请号:US18558726
申请日:2022-05-06
IPC分类号: C07C235/20 , A61K31/16 , A61K31/165 , A61K31/397 , A61K31/40 , A61K31/42 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/455 , A61K31/4965 , A61K31/50 , A61K31/505 , A61K31/5375 , A61P25/00 , C07C235/16 , C07C235/22 , C07C235/24 , C07C243/28 , C07C255/29 , C07C259/06 , C07C313/02 , C07C317/28 , C07D205/04 , C07D213/75 , C07D237/20 , C07D237/22 , C07D239/42 , C07D241/20 , C07D261/14 , C07D295/18 , C07D305/08
CPC分类号: C07C235/20 , A61K31/16 , A61K31/165 , A61K31/397 , A61K31/40 , A61K31/42 , A61K31/44 , A61K31/4406 , A61K31/4409 , A61K31/455 , A61K31/4965 , A61K31/50 , A61K31/505 , A61K31/5375 , A61P25/00 , C07C235/16 , C07C235/22 , C07C235/24 , C07C243/28 , C07C255/29 , C07C259/06 , C07C313/02 , C07C317/28 , C07D205/04 , C07D213/75 , C07D237/20 , C07D237/22 , C07D239/42 , C07D241/20 , C07D261/14 , C07D295/18 , C07D305/08 , C07C2601/02 , C07C2601/14
摘要: Provided herein are fatty acid amide (FAAH) cleavable prodrugs of thyromimetics and pharmaceutical compositions comprising these compounds with at least one pharmaceutically acceptable excipient further comprising a peripherally restricted FAAH inhibitor.
-
公开(公告)号:US20240252500A1
公开(公告)日:2024-08-01
申请号:US18423232
申请日:2024-01-25
IPC分类号: A61K31/5375 , A61K9/00 , A61K31/192 , A61P17/04
CPC分类号: A61K31/5375 , A61K9/0014 , A61K9/0053 , A61K31/192 , A61P17/04
摘要: Treatment of chronic pruritic dermatoses by administration of seladelpar or a salt thereof, or by administration of mavodelpar or a salt thereof.
-
公开(公告)号:US20240199535A1
公开(公告)日:2024-06-20
申请号:US18554365
申请日:2022-04-08
申请人: IMMUNIC AG
发明人: Christian GEGE , Hella KOHLHOF , Andreas MÜHLER , Daniel VITT
IPC分类号: C07C233/75 , A61K31/16 , A61K31/167 , A61K31/341 , A61K31/381 , A61K31/426 , A61K31/437 , A61K31/44 , A61K31/472 , A61K31/5375 , A61P31/14 , C07C233/74 , C07D213/68 , C07D213/73 , C07D217/04 , C07D265/30 , C07D277/34 , C07D307/30 , C07D333/40 , C07D471/04
CPC分类号: C07C233/75 , A61K31/16 , A61K31/167 , A61K31/341 , A61K31/381 , A61K31/426 , A61K31/437 , A61K31/44 , A61K31/472 , A61K31/5375 , A61P31/14 , C07C233/74 , C07D213/68 , C07D213/73 , C07D217/04 , C07D265/30 , C07D277/34 , C07D307/30 , C07D333/40 , C07D471/04
摘要: The invention relates to novel deuterated compounds of Formula (I)
and their use as medicaments.-
公开(公告)号:US20240156846A1
公开(公告)日:2024-05-16
申请号:US18113981
申请日:2023-02-24
申请人: Arizona Board of Regents on Behalf of the University of Arizona , THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
发明人: Rui Chang , Patrick T. Ronaldson , Qianying He , Wassim ELYAMAN , Elizabeth BRADSHAW , Kuixi ZHU
IPC分类号: A61K31/7028 , A61K31/26 , A61K31/357 , A61K31/404 , A61K31/4409 , A61K31/5375 , A61K45/06 , A61P25/28
CPC分类号: A61K31/7028 , A61K31/26 , A61K31/357 , A61K31/404 , A61K31/4409 , A61K31/5375 , A61K45/06 , A61P25/28
摘要: This invention relates generally to neurodegenerative diseases and conditions (e.g., Alzheimer's disease) characterized with dysfunctional energetic function, unregulated microglia phagocytic activity and other related de-regulated biological functions. This invention further relates to methods and compositions for treating such neurodegenerative diseases and conditions with pharmaceutical compositions capable of protecting neurons from cell death and unregulated microglia phagocytic activity.
-
公开(公告)号:US11975086B2
公开(公告)日:2024-05-07
申请号:US17809661
申请日:2022-06-29
申请人: KAO CORPORATION
发明人: Toshiaki Ozawa , Takaya Sakai , Mariko Miyoshi , Daisuke Furukawa , Aya Shirai
IPC分类号: A61K8/41 , A61K8/36 , A61K8/37 , A61K8/39 , A61K8/44 , A61K8/46 , A61K8/49 , A61K31/075 , A61K31/08 , A61K31/133 , A61K31/198 , A61K31/225 , A61K31/23 , A61K31/231 , A61K31/25 , A61K31/351 , A61K31/5375 , A61K45/06 , A61P17/00 , A61P17/10 , A61Q19/00 , A61Q19/10
CPC分类号: A61K8/41 , A61K8/361 , A61K8/37 , A61K8/375 , A61K8/39 , A61K8/44 , A61K8/463 , A61K8/466 , A61K8/49 , A61K8/498 , A61K31/075 , A61K31/08 , A61K31/133 , A61K31/198 , A61K31/225 , A61K31/23 , A61K31/231 , A61K31/25 , A61K31/351 , A61K31/5375 , A61K45/06 , A61P17/00 , A61P17/10 , A61Q19/00 , A61Q19/10 , A61K2800/596
摘要: A method for removing keratotic plugs capable of sufficiently exhibiting an excellent keratotic plug-removing effect without a burden, such as pam and of irritation, on the skin. The method comprises applying a composition comprising (X) one or more selected from (X1) 2-amino-2-hydroxymethyl-1,3-propanediol, (X2) 2-amino-2-methyl-1-propanol, and (X3) 2-amino-2-methyl-1,3-propanediol and a nonionic surfactant to the skin.
-
公开(公告)号:US20240130984A1
公开(公告)日:2024-04-25
申请号:US18492627
申请日:2023-10-23
发明人: Yun YEN , Jing-Ping LIOU , Chien Huang LIN
IPC分类号: A61K31/166 , A61K9/20 , A61K9/48 , A61K31/40 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4184 , A61K31/426 , A61K31/437 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/47 , A61K31/4706 , A61K31/495 , A61K31/4965 , A61K31/505 , A61K31/519 , A61K31/5375 , A61K45/06 , A61P11/00 , C07C15/00
CPC分类号: A61K31/166 , A61K9/20 , A61K9/48 , A61K31/40 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4184 , A61K31/426 , A61K31/437 , A61K31/44 , A61K31/4402 , A61K31/4406 , A61K31/4409 , A61K31/4453 , A61K31/47 , A61K31/4706 , A61K31/495 , A61K31/4965 , A61K31/505 , A61K31/519 , A61K31/5375 , A61K45/06 , A61P11/00 , C07C15/00 , A61K9/0019
摘要: The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.
-
-
-
-
-
-
-
-
-